Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial.
Tim C Jansen, Jasper van Bommel, F Jeanette Schoonderbeek...
https://pubmed.ncbi.nlm.nih.gov/20463176/Actively Recruiting
Led by University Hospital, Clermont-Ferrand · Updated on 2026-10-28
750
Participants Needed
29
Research Sites
4 weeks
Total Duration
Sepsis is a serious condition caused by an uncontrolled response to infection that leads to dangerous organ failure. Septic shock, the most severe form, involves low blood pressure and poor tissue oxygenation. Early treatment to improve blood flow and oxygen delivery is vital to prevent further organ damage and death. This trial compares two methods for guiding early treatment in adults with septic shock one using the difference in carbon dioxide pressure between venous and arterial blood CO2 gap and the other based on blood lactate levels, which are commonly used but not direct markers of tissue oxygen delivery. Participants will be randomly assigned to one of two groups. The first group will receive treatment guided by keeping the CO2 gap below 6 mmHg using a step-by-step approach with blood samples taken every 2 to 4 hours. The second group will have treatment aimed at reducing lactate levels by 20% every 2 to 4 hours, following current sepsis guidelines. Treatments include standard care with adjustments based on these measurements, such as use of medications like dobutamine or blood transfusions. The study takes place in intensive care units and monitors patients closely during their early resuscitation phase. Participants will be observed daily for 28 days after starting the study to assess survival and organ function. Researchers will collect blood samples regularly and evaluate clinical scores related to organ health. The main outcome is death from any cause within 28 days. Secondary outcomes include various measures of treatment effectiveness and safety. The study will last until the end of 2027, with careful monitoring and data collection to determine which resuscitation strategy may improve survival in septic shock patients.
CONDITIONS
Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock
L
Lise Laclautre
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Clermont-Ferrand
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 28 days
Participants receive early resuscitation guided by either the CO2 gap or lactate levels, with blood samples taken every 2 to 4 hours to adjust treatment accordingly.
Daily assessments and blood sampling
Duration - 28 days
Participants are monitored for survival and organ function for up to 28 days after starting treatment.
Daily follow-up visits or assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tim C Jansen, Jasper van Bommel, F Jeanette Schoonderbeek...
https://pubmed.ncbi.nlm.nih.gov/20463176/Alessandro Protti, Serge Masson, Roberto Latini...
https://pubmed.ncbi.nlm.nih.gov/29787743/Christopher W Seymour, Vincent X Liu, Theodore J Iwashyna...
https://pubmed.ncbi.nlm.nih.gov/26903335/Xiaochun Lyu, Qianghong Xu, Guolong Cai...
https://pubmed.ncbi.nlm.nih.gov/25916923/Andrew S Levey, Cassandra Becker, Lesley A Inker
https://pubmed.ncbi.nlm.nih.gov/25710660/STARRT-AKI Investigators, Canadian Critical Care Trials Group, Australian and New Zealand Intensive Care Society Clinical Trials Group...
https://pubmed.ncbi.nlm.nih.gov/32668114/Pierre-Francois Laterre, Scott M Berry, Allan Blemings...
https://pubmed.ncbi.nlm.nih.gov/31577035/Gustavo A Ospina-Tascón, Diego F Bautista-Rincón, Mauricio Umaña...
https://pubmed.ncbi.nlm.nih.gov/24330804/Alan E Jones, Nathan I Shapiro, Stephen Trzeciak...
https://pubmed.ncbi.nlm.nih.gov/20179283/Andrew Rhodes, Laura E Evans, Waleed Alhazzani...
https://pubmed.ncbi.nlm.nih.gov/28101605/University Hospital, Clermont-Ferrand
Lead Sponsor